UK NICE Changes Mind On Ocrevus After Roche Drops Price
Executive Summary
Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.
You may also be interested in...
NHS England Hails Biggest CAR-T Uptake In Europe
Pharma must “speak the same language” as the National Health Service for “transactable” negotiations.
NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.
Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing
Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.